TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
29.55
+0.41 (1.41%)
At close: Jan 17, 2025, 4:00 PM
29.32
-0.23 (-0.79%)
After-hours: Jan 17, 2025, 7:04 PM EST
TG Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TG Therapeutics stock have an average target of 40.67, with a low estimate of 22 and a high estimate of 55. The average target predicts an increase of 37.63% from the current stock price of 29.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 25, 2024.
Analyst Ratings
The average analyst rating for TGTX stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $30 → $43 | Buy | Maintains | $30 → $43 | +45.52% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +86.13% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -25.55% | Nov 5, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +69.20% | Oct 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +65.82% | Sep 18, 2024 |
Financial Forecast
Revenue This Year
335.77M
from 233.66M
Increased by 43.70%
Revenue Next Year
560.44M
from 335.77M
Increased by 66.91%
EPS This Year
0.15
from 0.09
Increased by 64.25%
EPS Next Year
0.98
from 0.15
Increased by 570.43%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 427.8M | 663.8M | 948.5M | |||
| Avg | 335.8M | 560.4M | 764.6M | |||
| Low | 308.2M | 462.6M | 627.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 83.1% | 97.7% | 69.2% | |||
| Avg | 43.7% | 66.9% | 36.4% | |||
| Low | 31.9% | 37.8% | 11.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.70 | 1.37 | 3.31 | |||
| Avg | 0.15 | 0.98 | 2.01 | |||
| Low | 0.01 | 0.44 | 0.95 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 688.1% | 830.9% | 236.5% | |||
| Avg | 64.3% | 570.4% | 104.8% | |||
| Low | -89.0% | 200.8% | -3.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.